These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15668750)

  • 1. The remittive effects of alefacept.
    Krueger GG
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():10-3. PubMed ID: 15668750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alefacept therapy produces remission for patients with chronic plaque psoriasis.
    Krueger GG; Ellis CN
    Br J Dermatol; 2003 Apr; 148(4):784-8. PubMed ID: 12752139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and use of alefacept to treat psoriasis.
    Krueger GG; Callis KP
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
    Moul DK; Routhouska SB; Korman NJ
    J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.
    Krueger GG
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():17-24. PubMed ID: 12795771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alefacept: a novel biologic in the treatment of psoriasis.
    Liu CM; McKenna JK; Krueger GG
    Drugs Today (Barc); 2004 Dec; 40(12):961-74. PubMed ID: 15645008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use.
    Korman NJ; Moul DK
    Semin Cutan Med Surg; 2005 Mar; 24(1):10-8. PubMed ID: 15900794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
    Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
    J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
    Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
    Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alefacept: an expert review concerning the treatment of psoriasis.
    Langley RG; Cherman AM; Gupta AK
    Expert Opin Pharmacother; 2005 Oct; 6(13):2327-33. PubMed ID: 16218892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.
    Krueger GG
    Expert Opin Biol Ther; 2002 Apr; 2(4):431-41. PubMed ID: 11955280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
    Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of alefacept in the treatment of psoriasis.
    Wong VK; Lebwohl M
    Skin Therapy Lett; 2003 Sep; 8(6):1-2, 7. PubMed ID: 14610613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of alefacept in the treatment of chronic plaque psoriasis.
    Gordon KB; Valentine J
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():3-9. PubMed ID: 15668749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.